BrightInsight for Biopharma

"We are excited to partner with BrightInsight, strengthening our commitment to addressing unmet needs in the rare disease space, and putting patients at the forefront of our innovations."

Colin Lake, VP, Head of Digital Business Transformation Neurology, UCB

"Normally, diagnostics are a one way street...with digital tools, you have the opportunity for a feedback loop, and to continuously improve the models going forward...This helps us determine in which occasions medicines don't work, so we can start developing the next generation of treatments."

Joachim Reischl, Vice President, Head of Diagnostic Sciences, AstraZeneca

"After conducting a rigorous evaluation, we selected BrightInsight because it has the only regulated solution with a robust Quality Management System and a comprehensive list of privacy and security certifications. BrightInsight’s Platform allows us to focus on therapeutic innovation, rather than the underlying digital technology."

Brian Johnson, Director, Digital Health, CSL Behring

"Medical-grade digital health platforms like BrightInsight are key to helping us improve the conversation between people with diabetes and their caregivers."

Anders Dyhr Toft, Corporate Vice President, Commercial Innovation, Novo Nordisk

"If you leverage a solution like BrightInsight that meets the most stringent requirements and maintains compliance as part of their managed service, you don’t have to worry about your regulated digital solutions in the U.S. versus Europe versus U.K. and so on. You just know they’re compliant."

Paul Upham, Head of Smart Devices, Roche/Genentech